Delving into the Latest Updates on Pegcetacoplan with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Pegcetacoplan (USAN/INN), APL 2, APL-2

+ [5]

Target

C3

Action

inhibitors

Mechanism

C3 inhibitors(Complement C3 inhibitors)

Therapeutic Areas

Congenital DisordersEye DiseasesHemic and Lymphatic Diseases+ [5]

Active Indication

C3 glomerulopathyGlomerulonephritis, MembranoproliferativeGeographic Atrophy+ [9]

Inactive Indication

Amyotrophic Lateral SclerosisGlomerulonephritis, IGAIdiopathic Membranous Glomerulonephritis+ [4]

Originator Organization

Apellis Pharmaceuticals, Inc.

Active Organization

Swedish Orphan Biovitrum AB

Apellis Pharmaceuticals, Inc.Apellis Australia Pty Ltd.

+ [3]

Inactive Organization-

License Organization

SFJ Pharmaceuticals, Inc.

Swedish Orphan Biovitrum Ltd.

Acino International AG

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (14 May 2021),

Hemoglobinuria, Paroxysmal

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Orphan Drug (United Kingdom), Priority Review (United States)

Login to view timeline

Structure/Sequence

Sequence Code 550935032

Source: *****

This is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior to randomizing for phase 3. The phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, multicenter study in adults and adolescents diagnosed with FSGS.

Start Date01 Dec 2025

Sponsor / Collaborator

Apellis Pharmaceuticals, Inc.

NCT07214298

/ Not yet recruitingPhase 1/2IIT

A Phase I/II Study of Complement Inhibition in Pancreatic Ductal Adenocarcinoma

This phase I/II trial tests the effect of pegcetacoplan in combination with oxaliplatin, irinotecan, leucovorin, and fluorouracil (mFOLFIRINOX) in treating patients with pancreatic ductal adenocarcinoma (PDAC) that has spread from where it first started (primary site) to other places in the body (metastatic). Pegcetacoplan works by targeting the immune complement process, a part of the immune system that defends against bacteria and may limit tumor progression and improve the immune system's response against tumor cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Leucovorin is a drug used to lessen the toxic effects of substances that block the action of folic acid. Leucovorin is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent. Fluorouracil stops cells from making DNA and it may kill tumor cells. It is a type of antimetabolite. Giving pegcetacoplan in combination with mFOLFIRINOX may be safe, tolerable, and/or effecting in treating patients with metastatic PDAC. This trial also evaluates the effect of pegcetacoplan on the incidence of major thrombotic events and the resulting complications. Thrombosis is a common complication in patients with PDAC. Thrombosis occurs when blood clots block veins or arteries. Complications of thrombosis, such as stroke or heart attack, can be life-threatening. Giving pegcetacoplan may help prevent blood clots from forming and decrease the risk of major thrombotic events.

Start Date01 Dec 2025

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

NCT07214740

/ CompletedPhase 3

A Phase 3B, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety of Pegcetacoplan in a Prefilled Syringe in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)

Start Date24 Oct 2025

Sponsor / Collaborator

Apellis Pharmaceuticals, Inc.

100 Clinical Results associated with Pegcetacoplan

Login to view more data

100 Translational Medicine associated with Pegcetacoplan

Login to view more data

100 Patents (Medical) associated with Pegcetacoplan

Login to view more data

202

Literatures (Medical) associated with Pegcetacoplan

01 Jan 2026·AMERICAN JOURNAL OF OPHTHALMOLOGY

Real-World Experience With Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration

Article

Author: Le, Viet Hoan ; El-Mulki, Omar S ; Zhang, Yi ; Kastner, James ; Hiya, Farhan ; Beqiri, Sara ; Rosenfeld, Philip J ; Berni, Alessandro ; O'Brien, Robert C ; Liu, Jeremy ; Shen, Mengxi ; Gregori, Giovanni ; Herrera, Gissel ; Yehoshua, Zohar ; Nicola, Maura Di ; Wang, Ruikang K ; Cheng, Yuxuan ; Dubovy, Sander R ; Trivizki, Omer ; Kumar, Sivathanu

PURPOSE:

To report on the real-world experience of using intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) in age-related macular degeneration (AMD).

DESIGN:

Retrospective interventional case series.

METHODS:

Eyes with symptomatic GA secondary to AMD were treated with 15 mg of intravitreal pegcetacoplan and participated in an ongoing prospective swept-source optical coherence tomography angiography (SS-OCTA) imaging study. All eyes underwent SS-OCTA imaging before and during pegcetacoplan therapy to assess for GA lesion size, the presence of nonexudative macular neovascularization (MNV), and the onset of exudation. The growth rate of GA and best-corrected visual acuity (BCVA) were assessed for eyes followed for 1 year.

RESULTS:

From April 12, 2023, to November 11, 2024, 154 eyes were injected with pegcetacoplan, and 103 eyes had 1-year follow-up. At baseline, 11 eyes had been previously treated with anti-VEGF therapy, and 9 eyes were diagnosed with treatment-naïve nonexudative MNV by SS-OCTA. Each eye received an average of 10 ± 2 injections, with an average interval of 1.2 months between injections. For the 97 eyes with 1 year of follow-up and measurable GA, the square-root (sqrt) GA growth rate after pegcetacoplan treatment was 0.24 ± 0.15 mm/year. Of these 97 eyes, 63 eyes had prior annual visits before pegcetacoplan treatment was started. In these eyes, the annual sqrt GA growth rate was 0.33 ± 0.22 mm/year before pegcetacoplan and 0.21 ± 0.12 mm/year after pegcetacoplan, resulting in a 37% decrease in the growth rate (P < .001). There were no significant differences in GA growth rate between foveal and nonfoveal GA, either before or after the use of pegcetacoplan (all P ≥ .80). The mean BCVA declined from 63 ± 14 to 59 ± 15 letters over 1 year (P = .001), with no significant difference between foveal and nonfoveal GA (P = .36). Among the 29 eyes developing exudation during pegcetacoplan treatment, 19 (66%) had no evidence of any detectable MNV at baseline and during treatment on SS-OCTA.

CONCLUSIONS:

Eyes treated with pegcetacoplan after 1 year had a 37% reduction in GA growth rate compared with their prior annual growth rate. Pegcetacoplan slowed the growth for foveal and nonfoveal GA at a similar rate. Most of the pegcetacoplan-associated exudation was not due to detectable MNV.

31 Dec 2025·Hematology

Successful switch from pegcetacoplan to iptacopan after repeated severe breakthrough hemolysis events – case report

Article

Author: Füreder, Wolfgang ; Reinisch, Andreas

OBJECTIVES:

A subset of paroxysmal nocturnal hemoglobinuria (PNH) patients develops clinically relevant extravascular hemolysis when treated with complement C5 inhibitors. These patients may benefit proximal complement inhibitors such as pegcetacoplan, danicopan or iptacopan. No studies comparing these substances are available. Breakthrough hemolysis (BTH) - defined by exacerbation of intravascular hemolysis despite complement inhibition - can be severe especially in patients treated with proximal complement inhibitors.

METHODS:

We report on a PNH patient who had suffered repeated episodes of severe BTH with acute renal failure during 1 year of treatment with pegcetacoplan. The patient was switched to iptacopan and followed also for 1 year.

RESULTS:

After switching to iptacopan, no further BTH occurred for the duration of 12 months follow up. The patient maintained stable hemoglobin and reticulocyte counts as well as lactate dehydrogenase (LDH) levels within the normal range.

DISCUSSION:

Despite dose escalation of pegcetacoplan, BTH recurred in our patient. Therefore, an alternative therapy was warranted. During iptacopan therapy - chosen due to patient preference -no further BTH occurred. However, more data from a larger number of patients are needed.

CONCLUSION:

A switch to iptacopan may be an option for pegcetacoplan treated patients who experience repeated BTH in spite of dose escalation.

22 Sep 2025·Immunotherapy

Plain language summary of disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT

Article

Author: Reiter, Gregor S. ; Mai, Julia ; Scheibler, Lukas ; Sadeghipour, Amir ; Schmidt-Erfurth, Ursula ; Riedl, Sophie ; Foos, Emma ; Vogl, Wolf-Dieter ; McKeown, Alex ; Bogunovic, Hrvoje

347

News (Medical) associated with Pegcetacoplan

15 Dec 2025

·www.fiercebiotech.com

Aviceda geographic atrophy hopeful fails to top Astellas\' med in phase 2

Despite the fail, Aviceda still plans to test its lead asset in two sham-controlled phase 3 trials in 2026.\n Aviceda Therapeutics has hit a snag in its goal to deliver a new treatment for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay (avacincaptad pegol) at slowing the rate of retina lesion growth, missing the primary endpoint of a phase 2 trial.The trial enrolled 300 patients with GA and treated them with monthly eye injections of either Izervay or AVD-104 at low or high doses.\"The study did not meet its primary endpoint, which was designed to assess non-inferiority,\" a company spokesperson told Fierce Biotech. \"No statistical differences in GA lesion growth rates were observed across the three study arms.\"AVD-104 led to no serious adverse events, Aviceda reported in a Dec. 15 release, with the most common side effect being eye floaters. AVD-104 is a nanoparticle adorned with polysialic acid, designed to bind to receptors on the surfaces of overactive immune cells like macrophages that cause eye inflammation in GA.Though it failed to top Izervay, AVD-104 did reduce the growth rate of GA lesions by 31% compared to previously published sham-treatment rates from Izervay’s phase 3 trial, according to Aviceda. The company described this finding as “clinically meaningful.” In addition, the company highlighted that patients given AVD-104 were able to read an average of 0.6 more letters in a visual acuity test after 12 months of treatment.“These results reinforce our belief that AVD-104 can provide meaningful functional vision benefit while reducing lesion progression, and has the potential to become a differentiated therapy addressing a significant unmet medical need for patients living with GA,” Aviceda CEO Jeffrey Nau, Ph.D., said in the release. Despite the failure, which Aviceda attributed to “imbalances in key baseline lesion characteristics across treatment arms,” the company still plans to test its lead asset in two sham-controlled phase 3 trials in 2026, according to the release. The Massachusetts-based biotech closed a $207.5 million series C in January to support its phase 3 vision.Aviceda was also testing the nanoparticle in a phase 2 trial for diabetic macular edema, but halted the study early due to “insufficient study drug supply and study funding constraints,” according to the clinicaltrials.gov database.GA has been a tough indication for pharma to crack. Roche blockbuster hopeful lampalizumab flopped in a critical phase 3 trial in 2017, with the Swiss pharma subsequently ditching the asset. Novartis scrapped its own GA candidate, acquired from Gyroscope Therapeutics, in September 2023 because of weak data.And in September 2024, Alkeus Pharmaceuticals reported that its oral candidate failed to reduce GA lesion growth in a phase 3 trial, with the company nevertheless declaring the results “clinically meaningful.”Apellis\' Syfovre (pegcetacoplan) was the first GA drug to break through, securing FDA approval in February 2023. However, the med was flagged by the agency for rare cases of severe eye inflammation that can lead to blindness just months later. Astellas picked up Izervay through the $5.9 billion acquisition of Iveric Bio in March 2023, garnering an approval of its own that August.Neither Izervay nor Syfovre is able to restore vision, and injections of both come with the risk of side effects like inflammation, bleeding and blurred sight.Outside of therapeutics, Science Corp. announced in October that its retinal implant was able to give GA patients some vision back in a clinical trial.Editor\'s note: This story was updated at 4:00 p.m. ET with a statement from Aviceda.

Phase 3AcquisitionPhase 2Drug ApprovalClinical Result

12 Dec 2025

·endpoints.news

CHMP calls to reject Anavex's Alzheimer’s pill over impurities, side effects and weak efficacy

As part of a batch of recommendations issued Friday, the European Medicines Agency’s human medicines committee (CHMP) recommended rejecting Anavex’s Alzheimer’s disease drug, issuing a scathing review of the pill’s safety and efficacy issues. The committee said it was concerned that the pill, called blarcamesine, could contain cancer-causing impurities. In addition, its main clinical study failed to meet its objective, and a “high proportion of patients” stopped taking the drug because of central nervous system side effects. Last month Anavex said it planned to request a reexamination of blarcamesine from the European regulators, after CHMP warned a negative opinion was likely. Anavex has 15 days to file for reexamination. As part of Friday’s package of actions, the committee also recommended five new medicines and 10 label expansions. GSK secured a positive opinion for its RSV vaccine Arexvy to be expanded to patients 18 years or older, rather than its previous approval for just people aged 50 or over. Arexvy was approved by the European Medicines Agency in June 2023. This brings the RSV vaccine to an equal footing with its competitors: Pfizer’s Abrysvo and Moderna’s mResvia, which have both already been approved for adults aged 18 or older. GSK’s Exdensur also got a positive CHMP opinion for adults and adolescents 12 years and older with severe eosinophilic asthma as well as for severe chronic rhinosinusitis with nasal polyps. Depemokimab is currently under review by the FDA, with a PDUFA date of Dec. 16. CHMP gave a positive opinion for four other new medicines: CHMP recommended nine other label expansions:

Drug ApprovalVaccineAccelerated Approval

12 Dec 2025

·www.sobi.com

Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

· Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN · If approved, Aspaveli (pegcetacoplan) would be the first C3G and primary IC-MPGN treatment for patients 12 and older Sobi® (STO: SOBI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The positive opinion from the CHMP is now referred to the European Commission for an approval decision, which is expected in the first quarter of 2026. Sobi and its partner Apellis Pharmaceuticals, Inc. have global co-development rights for systemic pegcetacoplan. “The CHMP’s positive opinion for Aspaveli represents an important milestone for people living with C3G or primary IC-MPGN in Europe, two severe and rare kidney diseases with limited treatment options and a high risk of kidney failure,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. “If approved, Aspaveli would become the first therapy for patients 12 years and older with these serious kidney diseases, which often affect adolescents and young adults. We look forward to the European Commission’s decision and to the opportunity to make a meaningful difference in the lives of patients and their families.” C3G and primary IC-MPGN are rare kidney diseases affecting approximately 8,000 patients in Europe. More than half of people living with C3G or primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or dialysis therapy.1-3 The CHMP recommendation is based on positive results from the Phase 3 VALIANT study, in which Aspaveli demonstrated benefits across three key markers of disease, including significant reduction in proteinuria, stabilisation of kidney function, and substantial clearance of C3 deposits. These positive results were recently published in The New England Journal of Medicine.6 About C3 Glomerulopathy (C3G) and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) C3G and primary IC-MPGN are rare and debilitating kidney diseases that can lead to kidney failure. Excessive C3 deposits are a key marker of disease activity, which can lead to kidney inflammation, damage, and failure. Approximately 50% of people living with C3G or primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or dialysis therapy.1-3 Additionally, approximately 90% of patients who previously received a kidney transplant will experience disease recurrence.4 The diseases are estimated to affect 5,000 people in the United States and up to 8,000 in Europe.5 About the VALIANT StudyThe VALIANT Phase 3 study (NCT05067127) was a randomised, placebo-controlled, double-blinded, multi-center study that evaluated pegcetacoplan efficacy and safety in 124 patients who were 12 years of age and older with C3G or primary IC-MPGN. It is the largest single trial conducted in these populations and the only study to include paediatric and adult patients, with native and post-transplant kidneys. Study participants were randomised to receive pegcetacoplan or placebo twice weekly for 26 weeks. Following this 26-week randomised controlled period, patients were able to proceed to a 26-week open-label phase in which all patients received pegcetacoplan. The primary endpoint of the study was the log transformed ratio of urine protein-to-creatinine ratio (UPCR) at Week 26 compared to baseline. About Aspaveli®/Empaveli® (pegcetacoplan)Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. It is the first treatment approved in the United States for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. Aspaveli/Empaveli is also approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the United States, European Union, and other countries globally, and for adults and adolescents with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in Saudi Arabia, South Korea and Switzerland. About the Sobi® and Apellis® Collaboration Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan. Apellis has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. References 1. Smith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143. 2. Servais A, et al. Kidney Int. 2012;82(4):454-464. 3. Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117. 4. Tarragón, B, et al. C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation. Clinical Journal of the American Society of Nephrology. August 2024; 19(8)1005-1015. doi: 10.2215/CJN.0000000000000474. 5. Data on file using literature consensus. 6. Fakhouri F, et al. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. New England Journal of Medicine. Published December 2025. We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care. We contribute to societies by improving access to treatment of rare diseases. Find out more about our business and financial performance. Here we present our most recent press releases, stories, news articles, and images. Every day, we work actively to find better ways to understand and meet patient needs.

Clinical ResultPhase 3Drug ApprovalASH

100 Deals associated with Pegcetacoplan

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11613	Pegcetacoplan	B03XA	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
C3 glomerulopathy	United States	Apellis Pharmaceuticals, Inc.	07 Oct 2024
Glomerulonephritis, Membranoproliferative	United States	Apellis Pharmaceuticals, Inc.	07 Oct 2024
Geographic Atrophy	United States	Apellis Pharmaceuticals, Inc.	17 Feb 2023
Hemoglobinuria, Paroxysmal	United States	Apellis Pharmaceuticals, Inc.	14 May 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulosclerosis, Focal Segmental	Phase 3	United States	Apellis Pharmaceuticals, Inc.	01 Dec 2025
Delayed Graft Function	Phase 3	-	Apellis Pharmaceuticals, Inc.	01 Sep 2025
Kidney Failure, Chronic	Phase 3	-	Apellis Pharmaceuticals, Inc.	01 Sep 2025
Cold Agglutinin Disease	Phase 3	United States	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Japan	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Austria	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Belgium	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Canada	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Finland	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Germany	Swedish Orphan Biovitrum AB	20 Oct 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05776472 (COMPLETE, ASH2025)	Phase 4	Hemoglobinuria, Paroxysmal	200	Pegcetacoplan (with a history of aplastic anemia)	vvriyoznuz(dsygtybrhp) = vlezkestpi ejzbdbrhmh (ewubmetmpj, 62.0 - 118.7) View more	Positive	06 Dec 2025
				Pegcetacoplan (without a history of aplastic anemia)	vvriyoznuz(dsygtybrhp) = rixfionnbr ejzbdbrhmh (ewubmetmpj, 81.8 - 136.6) View more
ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal	77	Pegcetacoplan (CI-experienced patients)	eacdilostf(pbcctvwtxe) = sntpiylcrb zbqcqpyjgv (zijhrrgwru ) View more	Positive	06 Dec 2025
				Pegcetacoplan (CI-naive patients)	eacdilostf(pbcctvwtxe) = xjwgetpllf zbqcqpyjgv (zijhrrgwru ) View more
ASH2025	Not Applicable	Thrombotic Microangiopathies	6	Pegcetacoplan	nlcrntxbbw(qwmzukgkjw) = pxzfdffqhb vgnieklrff (tlvwbzqpbt )	Positive	06 Dec 2025
ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal	24	Pegcetacoplan	xvsyrwcrrb(zjskrstuud) = bhtajqmrtk vyknlelcsa (voacjtnqaz ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal	15	Pegcetacoplan	nvrurvvumw(rtklhjeowg) = vmxdgkdbum wiypvmcrqt (hobvbtrpts, 1.8) View more	Positive	06 Dec 2025
				Iptacopan	nvrurvvumw(rtklhjeowg) = dbtedigqiw wiypvmcrqt (hobvbtrpts, 2.1) View more
NCT05067127 (VALIANT, N Engl J Med) Manual	Phase 3	Glomerulonephritis, Membranoproliferative \| C3 glomerulopathy	124	Pegcetacoplan	qjzidvbzuy(yfhpzbpjob) = wfgxzpbhne sdfmyxcoqx (czvwarofff, -74.9 to -57.2) View more	Positive	03 Dec 2025
				Placebo	qjzidvbzuy(yfhpzbpjob) = bjrdisdbdw sdfmyxcoqx (czvwarofff, -8.6 to 15.9) View more
NCT05148299 (CTgov)	Phase 2	Thrombotic Microangiopathies	12	Pegcetacoplan	qydlwllvbj(rujvrafaos) = qlnlvwwhkw hzbfqugyik (hsbysfpeec, 4448.067) View more	-	28 Nov 2025
NCT05096403 (CTgov)	Phase 3	Cold Agglutinin Disease	24	Pegcetacoplan (Pegcetacoplan Double Blind During Part A)	ffehnxayua = enjanxeavp xzyacakcpb (eftgjtozcx, wbdloywmwr - hfvhkogqpp) View more	-	30 Oct 2025
				Placebo matching Pegcetacoplan (Placebo Matching Pegcetacoplan-Double-blind During Part A)	ffehnxayua = glntmhzgic xzyacakcpb (eftgjtozcx, yiocryjaet - ortkyvyddd) View more
EURETINA2025	Not Applicable	Age Related Macular Degeneration	22	Pegcetacoplan 15mg monthly	yedughbtyi(ctebdgjdwz) = High-certainty evidence indicates that PEG or ACP do not confer significant benefit to low-luminance BCVA. vggwvgjvaa (suibblgtpn )	Negative	04 Sep 2025
				Pegcetacoplan 15mg every other month
NCT03525613 (OAKS, EURETINA2025)	Phase 3	Age Related Macular Degeneration \| Geographic Atrophy outer nuclear layer (ONL) \| external limiting membrane (ELM) \| ellipsoid zone layer (EZ) ... View more	453	Pegcetacoplan 15 mg per 0.1 mL intravitreal injection monthly	kasfeyrvwi(cptkmtgwoi) = tcdfontykd jgacjucxyy (wrqeddojxh ) View more	Positive	04 Sep 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.